Pathological Cardiac Hypertrophy Alters Intracellular Targeting of Phosphodiesterase Type 5 From Nitric Oxide Synthase-3 to Natriuretic Peptide Signaling
Author(s) -
Manling Zhang,
Eiki Takimoto,
Dongik Lee,
Célio X.C. Santos,
Taishi Nakamura,
Steven Hsu,
Aiyang Jiang,
Takahiro Nagayama,
Djahida Bedja,
Yuan Yuan,
Philip Eaton,
Ajay M. Shah,
David A. Kass
Publication year - 2012
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.112.090977
Subject(s) - medicine , intracellular , nitric oxide synthase , natriuretic peptide , phosphodiesterase , cardiac hypertrophy , nitric oxide , pathological , atrial natriuretic peptide , endocrinology , muscle hypertrophy , pharmacology , microbiology and biotechnology , enzyme , biochemistry , heart failure , biology
In the normal heart, phosphodiesterase type 5 (PDE5) hydrolyzes cGMP coupled to nitric oxide- (specifically from nitric oxide synthase 3) but not natriuretic peptide (NP)-stimulated guanylyl cyclase. PDE5 is upregulated in hypertrophied and failing hearts and is thought to contribute to their pathophysiology. Because nitric oxide signaling declines whereas NP-derived cGMP rises in such diseases, we hypothesized that PDE5 substrate selectivity is retargeted to blunt NP-derived signaling.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom